Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

Fig. 5

Kaplan-Meier curves for overall survival. The median overall survival was 25.1 months (95% confidence interval [CI], 22.3–27.6) for PE and 18.3 months (95% CI, 16.5–20.9) for PA (HR 0.56, 95%CI, 0.39–0.80; p = 0.001). *The hazard ratio was calculated using a Cox proportional hazards model, with the age, time since diagnosis, PSA level, alkaline phosphatase level, clinical stage at diagnosis, pathological stage at diagnosis, Gleason sum at diagnosis, mCRPC-related brain metastasis, ECOG status, and number of metastatic sites used as covariates and therapy as the time-dependent factor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us